# Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

> **NCT06261125** · PHASE2 · RECRUITING · sponsor: **Mian XI** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **RADIATION:** Stereotactic body radiotherapy
- **DRUG:** Adebrelimab
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06261125
- **Lead sponsor:** Mian XI
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-10
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06261125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06261125, "Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06261125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*